Literature DB >> 12130681

trans-Activation and repression properties of the novel nonsteroid glucocorticoid receptor ligand 2,5-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5-(1-methylcyclohexen-3-y1)-1H-[1]benzopyrano[3,4-f]quinoline (A276575) and its four stereoisomers.

Chun Wel Lin1, Masaki Nakane, Mike Stashko, Doug Falls, Jane Kuk, Loan Miller, Ruth Huang, Curtis Tyree, Jeffrey N Miner, John Rosen, Philip R Kym, Mike J Coghlan, George Carter, Ben C Lane.   

Abstract

Glucocorticoids are potent anti-inflammatory and immunosuppressant agents. However, they also produce serious side effects that limit their usage. It has been proposed that anti-inflammatory properties of glucocorticoids are caused mostly by repression of activator protein 1- and nuclear factor kappabeta-stimulated synthesis of inflammatory mediators, whereas most of their adverse effects are associated with trans-activation of genes involved with metabolic processes. Our laboratories have sought to discover novel glucocorticoid receptor (GR) ligands that have high repression but low trans-activation activities. We describe here cellular properties of 2,5-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5-(1-methylcyclohexen-3-y1)-1H-[1]benzopyrano[3,4-f]quinoline (A276575) and its four enantiomers. Similar to dexamethasone, A276575 exhibited high affinity for GR and potently repressed interleukin (IL) 1beta-stimulated IL-6 production in human skin fibroblasts, prostaglandin (PG) E(2) production in A549 human lung epithelial cells, and concanavalin A-induced monocyte proliferation. In contrast to dexamethasone, A276575 caused smaller induction of aromatase activity in human skin fibroblasts and antagonized dexamethasone-induced activation of an mouse mammary tumor virus-glucocorticoid-response element (GRE) reporter gene construct. Among the four enantiomers of A276575, the two (-)-enantiomers showed 10- to 30-fold higher affinities for GR than their respective (+)-enantiomers. Both (-)-Syn and (-)-Anti enantiomers of A276575 were potent inhibitors of IL-1beta-stimulated PGE2 production in A549 lung epithelial cells; unexpectedly, however, only the (-)-Anti enantiomer inhibited regulated on T-cell activation, normal T-cell expressed and secreted (RANTES) production in A549 cells. In summary, A276575 is a novel, nonsteroidal GR ligand that possesses high repression activities against inflammatory mediator production but has lower GRE trans-activation activities than traditional steroids. Differential repression of RANTES and PGE2 production in a cell by the two (-)-enantiomers of A276575 illustrates the complexity of repression by GR.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12130681     DOI: 10.1124/mol.62.2.297

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  10 in total

Review 1.  [Current insights into the development of new glucocorticoid receptor ligands].

Authors:  F Buttgereit; I-H Song; R H Straub; G-R Burmester
Journal:  Z Rheumatol       Date:  2005-04       Impact factor: 1.372

Review 2.  Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases.

Authors:  Ilse M E Beck; Wim Vanden Berghe; Linda Vermeulen; Keith R Yamamoto; Guy Haegeman; Karolien De Bosscher
Journal:  Endocr Rev       Date:  2009-11-04       Impact factor: 19.871

Review 3.  Social stress and asthma: the role of corticosteroid insensitivity.

Authors:  Angela Haczku; Reynold A Panettieri
Journal:  J Allergy Clin Immunol       Date:  2010-02-11       Impact factor: 10.793

Review 4.  Pharmacomimetics of exercise: novel approaches for hippocampally-targeted neuroprotective agents.

Authors:  A M Stranahan; Y Zhou; B Martin; S Maudsley
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

5.  A ligand-specific kinetic switch regulates glucocorticoid receptor trafficking and function.

Authors:  Peter J Trebble; James M Woolven; Ken A Saunders; Karen D Simpson; Stuart N Farrow; Laura C Matthews; David W Ray
Journal:  J Cell Sci       Date:  2013-05-17       Impact factor: 5.285

6.  Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile.

Authors:  Jeffrey N Miner; Bob Ardecky; Khalid Benbatoul; Kimberly Griffiths; Christopher J Larson; Dale E Mais; Keith Marschke; Jon Rosen; Eric Vajda; Lin Zhi; Andres Negro-Vilar
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-21       Impact factor: 11.205

Review 7.  Glucocorticoids: new mechanisms and future agents.

Authors:  Ian M Adcock
Journal:  Curr Allergy Asthma Rep       Date:  2003-05       Impact factor: 4.919

Review 8.  Discovery of Compound A--a selective activator of the glucocorticoid receptor with anti-inflammatory and anti-cancer activity.

Authors:  Ekaterina Lesovaya; Alexander Yemelyanov; Amanda C Swart; Pieter Swart; Guy Haegeman; Irina Budunova
Journal:  Oncotarget       Date:  2015-10-13

9.  11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess.

Authors:  Stuart A Morgan; Emma L McCabe; Laura L Gathercole; Zaki K Hassan-Smith; Dean P Larner; Iwona J Bujalska; Paul M Stewart; Jeremy W Tomlinson; Gareth G Lavery
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-02       Impact factor: 11.205

10.  A Novel Radioligand Reveals Tissue Specific Pharmacological Modulation of Glucocorticoid Receptor Expression with Positron Emission Tomography.

Authors:  Yangjie Huang; Ning Zhao; Yung-Hua Wang; Charles Truillet; Junnian Wei; Joseph E Blecha; Henry F VanBrocklin; Youngho Seo; Mohd Sayeed; Brian J Feldman; Rahul Aggarwal; Spencer C Behr; Hao Shao; David M Wilson; Javier E Villanueva-Meyer; Jason E Gestwicki; Michael J Evans
Journal:  ACS Chem Biol       Date:  2020-04-15       Impact factor: 4.634

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.